Like in earlier studies, we were unable to demonstrate beneficial effects of monotherapy with an AT1 antagonist or ACE inhibitor on glomerulosclerosis (Mifsud et al., 2002; Roksnoer et al., 2016; Uijl et al., 2020), nor of their combined treatment. This evidence concerns the gene ACE and glomerulosclerosis.